Skip to main content
NCBI home page
Gut logoLink to Gut
. 1999 Jul;45(Suppl 1):I40–I44. doi: 10.1136/gut.45.2008.i40

Treatment after failure: the problem of "non-responders"

J Huang, R Hunt
PMCID: PMC1766657  PMID: 10457036

Full Text

The Full Text of this article is available as a PDF (89.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adamek R. J., Suerbaum S., Pfaffenbach B., Opferkuch W. Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. Am J Gastroenterol. 1998 Mar;93(3):386–389. doi: 10.1111/j.1572-0241.1998.00386.x. [DOI] [PubMed] [Google Scholar]
  2. Babian M., Nasef S., Soloway G. Gastrointestinal infarction as a manifestation of rheumatoid vasculitis. Am J Gastroenterol. 1998 Jan;93(1):119–120. doi: 10.1111/j.1572-0241.1998.119_c.x. [DOI] [PubMed] [Google Scholar]
  3. Bazzoli F., Zagari M., Pozzato P., Varoli O., Fossi S., Ricciardiello L., Alampi G., Nicolini G., Sottili S., Simoni P. Evaluation of short-term low-dose triple therapy for the eradication of Helicobacter pylori by factorial design in a randomized, double-blind, controlled study. Aliment Pharmacol Ther. 1998 May;12(5):439–445. doi: 10.1046/j.1365-2036.1998.00330.x. [DOI] [PubMed] [Google Scholar]
  4. Bell G. D., Bate C. M., Axon A. T., Tildesley G., Kerr G. D., Green J. R., Emmas C. E., Taylor M. D. Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. Aliment Pharmacol Ther. 1995 Oct;9(5):513–520. doi: 10.1111/j.1365-2036.1995.tb00414.x. [DOI] [PubMed] [Google Scholar]
  5. Buckley M. J., Xia H. X., Hyde D. M., Keane C. T., O'Morain C. A. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci. 1997 Oct;42(10):2111–2115. doi: 10.1023/a:1018882804607. [DOI] [PubMed] [Google Scholar]
  6. Gerbes A. L., Bilzer M., Gülberg V. Intrahepatic modulation of portal pressure and its role in portal hypertension. Role of endothelins. Digestion. 1998 Jul-Aug;59(4):410–412. doi: 10.1159/000007499. [DOI] [PubMed] [Google Scholar]
  7. Go M. F., Graham D. Y. Presence of the cagA gene in the majority of Helicobacter pylori strains is independent of whether the individual has duodenal ulcer or asymptomatic gastritis. Helicobacter. 1996 Jun;1(2):107–111. doi: 10.1111/j.1523-5378.1996.tb00019.x. [DOI] [PubMed] [Google Scholar]
  8. Goh K. L., Parasakthi N., Chuah S. Y., Cheah P. L., Lo Y. L., Chin S. C. Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? Aliment Pharmacol Ther. 1997 Dec;11(6):1115–1118. doi: 10.1046/j.1365-2036.1997.00248.x. [DOI] [PubMed] [Google Scholar]
  9. Graham D. Y., Lew G. M., Malaty H. M., Evans D. G., Evans D. J., Jr, Klein P. D., Alpert L. C., Genta R. M. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology. 1992 Feb;102(2):493–496. doi: 10.1016/0016-5085(92)90095-g. [DOI] [PubMed] [Google Scholar]
  10. Hachem C. Y., Clarridge J. E., Reddy R., Flamm R., Evans D. G., Tanaka S. K., Graham D. Y. Antimicrobial susceptibility testing of Helicobacter pylori. Comparison of E-test, broth microdilution, and disk diffusion for ampicillin, clarithromycin, and metronidazole. Diagn Microbiol Infect Dis. 1996 Jan;24(1):37–41. doi: 10.1016/0732-8893(95)00252-9. [DOI] [PubMed] [Google Scholar]
  11. Harris A. W., Pryce D. I., Gabe S. M., Karim Q. N., Walker M. M., Langworthy H., Baron J. H., Misiewicz J. J. Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. Aliment Pharmacol Ther. 1996 Dec;10(6):1005–1008. [PubMed] [Google Scholar]
  12. Huang J. Q., Hunt R. H. Review: eradication of Helicobacter pylori. Problems and recommendations. J Gastroenterol Hepatol. 1997 Aug;12(8):590–598. doi: 10.1111/j.1440-1746.1997.tb00491.x. [DOI] [PubMed] [Google Scholar]
  13. Hunt R. H. Eradication of Helicobacter pylori infection. Am J Med. 1996 May 20;100(5A):42S–51S. doi: 10.1016/s0002-9343(96)80228-2. [DOI] [PubMed] [Google Scholar]
  14. Hunt R., Thomson A. B. Canadian Helicobacter pylori consensus conference. Canadian Association of Gastroenterology. Can J Gastroenterol. 1998 Jan-Feb;12(1):31–41. doi: 10.1155/1998/170180. [DOI] [PubMed] [Google Scholar]
  15. Laine L., Estrada R., Trujillo M., Fukanaga K., Neil G. Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1996 Dec;10(6):1029–1033. doi: 10.1046/j.1365-2036.1996.111282000.x. [DOI] [PubMed] [Google Scholar]
  16. Lam S. K., Talley N. J. Report of the 1997 Asia Pacific Consensus Conference on the management of Helicobacter pylori infection. J Gastroenterol Hepatol. 1998 Jan;13(1):1–12. doi: 10.1111/j.1440-1746.1998.tb00537.x. [DOI] [PubMed] [Google Scholar]
  17. McNulty C. A., Gearty J. C., Crump B., Davis M., Donovan I. A., Melikian V., Lister D. M., Wise R. Campylobacter pyloridis and associated gastritis: investigator blind, placebo controlled trial of bismuth salicylate and erythromycin ethylsuccinate. Br Med J (Clin Res Ed) 1986 Sep 13;293(6548):645–649. doi: 10.1136/bmj.293.6548.645. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Misiewicz J. J., Harris A. W., Bardhan K. D., Levi S., O'Morain C., Cooper B. T., Kerr G. D., Dixon M. F., Langworthy H., Piper D. One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group. Gut. 1997 Dec;41(6):735–739. doi: 10.1136/gut.41.6.735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Miyaji H., Azuma T., Ito S., Suto H., Ito Y., Yamazaki Y., Sato F., Hirai M., Kuriyama M., Kato T. Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan. Aliment Pharmacol Ther. 1997 Dec;11(6):1131–1136. doi: 10.1046/j.1365-2036.1997.00258.x. [DOI] [PubMed] [Google Scholar]
  20. Moayyedi P., Langworthy H., Shanahan K., Tompkins D. S., Dixon M. F., Chalmers D. M., Axon A. T. Comparison of one or two weeks of lansoprazole, amoxicillin, and clarithromycin in the treatment of Helicobacter pylori. Helicobacter. 1996 Jun;1(2):71–74. doi: 10.1111/j.1523-5378.1996.tb00012.x. [DOI] [PubMed] [Google Scholar]
  21. Moayyedi P., Ragunathan P. L., Mapstone N., Axon A. T., Tompkins D. S. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol. 1998;33 (Suppl 10):62–65. [PubMed] [Google Scholar]
  22. Moshkowitz M., Konikoff F. M., Peled Y., Brill S., Hallak A., Tiomny E., Santo M., Bujanover Y., Gilat T. One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. Aliment Pharmacol Ther. 1996 Dec;10(6):1015–1019. doi: 10.1046/j.1365-2036.1996.96268000.x. [DOI] [PubMed] [Google Scholar]
  23. Mégraud F., Doermann H. P. Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. Gut. 1998 Jul;43 (Suppl 1):S61–S65. doi: 10.1136/gut.43.2008.s61. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Pipkin G. A., Williamson R., Wood J. R. Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori. Aliment Pharmacol Ther. 1998 Sep;12(9):823–837. doi: 10.1046/j.1365-2036.1998.00405.x. [DOI] [PubMed] [Google Scholar]
  25. Rinaldi V., Zullo A., Pugliano F., Valente C., Diana F., Attili A. F. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther. 1997 Oct;11(5):929–933. doi: 10.1046/j.1365-2036.1997.00228.x. [DOI] [PubMed] [Google Scholar]
  26. Tompkins D. S., Perkin J., Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter. 1997 Dec;2(4):185–187. doi: 10.1111/j.1523-5378.1997.tb00085.x. [DOI] [PubMed] [Google Scholar]
  27. Veldhuyzen van Zanten S., Hunt R. H., Cockeram A., Schep G., Malatjalian D., Sidorov J., Matisko A., Jewell D. Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance. Am J Gastroenterol. 1998 Jan;93(1):5–10. doi: 10.1111/j.1572-0241.1998.005_c.x. [DOI] [PubMed] [Google Scholar]
  28. Xia H. H., Kalantar J., Talley N. J. Metronidazole- and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites. J Gastroenterol Hepatol. 1998 Oct;13(10):1044–1049. doi: 10.1111/j.1440-1746.1998.tb00568.x. [DOI] [PubMed] [Google Scholar]
  29. Xia H., Keane C. T., Beattie S., O'Morain C. A. Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori. Antimicrob Agents Chemother. 1994 Oct;38(10):2357–2361. doi: 10.1128/aac.38.10.2357. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES